Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer

Published:2022-04-06 Issue:6 Volume:39 Page:2596-2613
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Satake Hironaga,Kagawa Yoshinori,Shinozaki Eiji,Tanizawa Yoshinori^ORCID,Jin Long,Cai Zhihong,Makiyama Akitaka

Funder

Eli Lilly Japan

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-022-02122-4.pdf

Reference44 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

2. Ministry of Health, Labour and Welfare. Cancer Information Service, National Cancer Center, Japan. Cancer Registry and Statistics. Vital Statistics of Japan. Page last updated July 28, 2021. https://ganjoho.jp/reg_stat/statistics/dl/index.html#mortality. Accessed 23 Nov 2021.

3. Ministry of Health, Labour and Welfare. Overview of the National Cancer Registry. 2016. www.mhlw.go.jp/content/10900000/000468976.pdf. Accessed 23 Nov 2021.

4. Ministry of Health, Labour and Welfare. Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan. Monitoring of Cancer Incidence in Japan (MCIJ). Page last updated July 28, 2021. https://ganjoho.jp/reg_stat/statistics/dl/index.html#incidence4pref. Accessed 23 Nov 2021.

5. Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1–42.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study;Targeted Oncology;2024-05-01

2. Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer;Cancers;2023-09-14

3. Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study;International Journal of Clinical Oncology;2023-06-01

4. Resveratrol Modulates Chemosensitisation to 5-FU via β1-Integrin/HIF-1α Axis in CRC Tumor Microenvironment;International Journal of Molecular Sciences;2023-03-05